

In the claims

Please cancel claims 1-72 without prejudice to their later renewal, and enter new claims 73-87 as follows:

Claims 1-72 Canceled.

Claim 73 (New): A method for generating an immune response to 85P1B3 in a mammal, comprising:

- a) contacting a cell of the mammal's immune system with an immunogenic portion of:
 - i) a protein having at least 90% homology to SEQ ID NO: 728; and/or
 - ii) a nucleotide sequence that encodes said protein; and
- b) inducing the cell to produce a response to the protein.

Claim 74 (New): The method of claim 73, wherein the protein having at least 90% homology to SEQ ID NO: 728 comprises at least one T cell epitope or at least one B cell epitope.

Claim 75 (New): The method of claim 73, wherein the cell is a B cell.

Claim 76) (New): The method of claim 75, wherein the response comprises generating an antibody from the B cell that specifically binds to the protein having at least 90% homology to SEQ ID NO: 728.

Claim 77 (New): The method of claim 73, wherein the cell is a cytotoxic T cell.

Claim 78 (New): The method of claim 77, wherein the response comprises killing by the cytotoxic T cell of an autologous cell that expresses the protein having at least 90% homology to SEQ ID NO: 728.

Claim 79 (New): The method of claim 73, wherein the cell is a helper T cell.

Claim 80 (New): The method of claim 79 wherein the response comprises secretion of cytokines from the helper T cell that facilitate the cytotoxic activity of a cytotoxic T cell or the antibody producing activity of a B cell.

Claim 81 (New): The method of claim 76, wherein the antibody is domain-specific.

Claim 82 (New): The method of claim 73, wherein the protein is expressed in a viral vector.

Claim 83 (New): The method of claim 73, wherein the nucleotide sequence is expressed in a viral vector.

Claim 84 (New): A method for inducing a cellular immune response in a subject to a protein having at least 90% homology to SEQ ID NO: 728 in a subject having a cancer expressing 85P1B3 protein, comprising administering to the subject a 85P1B3 protein or fragment thereof, or a 85P1B3 antigen presenting cell.

Claim 85 (New): The method of claim 84, wherein the cancer is prostate cancer, bladder cancer, kidney cancer, colon cancer, lung cancer, ovarian cancer, breast cancer, stomach cancer, or cervical cancer.

Claim 86 (New): The method of claim 84, wherein the step of administering generates a humoral immune response.

Claim 87 (New): The method of claim 84, wherein the 85P1B3 antigen presenting cell is a dendritic cell.